Chemical formula: C₃₃H₃₇N₅O₅ Molecular mass: 583.677 g/mol PubChem compound: 10531
Dihydroergotamine binds with high affinity to 5-HT1Dα and 5-HT1Dβ receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N02CA01 | Dihydroergotamine | N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CA Ergot alkaloids |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| DIHYDROERGOTAMINE MESYLATE Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
| MIGRANAL Nasal spray | FDA, National Drug Code (US) | MPI, US: SPL/Old |
Dihydroergotamine is an active ingredient of these brands:
United States (US)Austria (AT)
Brazil (BR)Canada (CA)
Ecuador (EC)
France (FR)
South Africa (ZA)
Tunisia (TN)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
